索拉非尼辅助治疗肝细胞癌预防复发的分子预测因素及3期STORM试验的预后因素
BIOSTORM生物标志物研究纳入STORM试验中188例接受索拉非尼(83例)或安慰剂(105例)的肝细胞癌患者肿瘤组织,评估分子标志物对复发预防的预测价值及预后因素。结果显示仅肝细胞pERK(HR=2.41;p=0.012)和微血管侵犯(HR=2.09;p=0.017)为独立预后因素,无突变、基因扩增或既往基因特征预测索拉非尼获益,新生成的146基因特征需进一步验证。
要点
- 肝细胞pERK(HR=2.41;p=0.012)和微血管侵犯(HR=2.09;p=0.017)是独立预后因素。
- 无突变、基因扩增或既往基因特征预测索拉非尼获益。
- 新生成146基因特征识别30%患者从索拉非尼获得RFS获益(交互作用p=0.04),需进一步验证。
核心结论
- 在BIOSTORM中,仅肝细胞pERK和微血管侵犯预测较差的RFS。
- 无突变、基因扩增或既往提出的基因特征预测索拉非尼获益。
- 新生成的多基因特征与索拉非尼改善RFS相关,需进一步验证。
研究设计与样本
- BIOSTORM为3期STORM试验的生物标志物伴随研究,收集188例随机接受索拉非尼(83例)或安慰剂(105例)患者的肿瘤组织。
- 分析包括基因表达谱、靶向外显子测序(19个已知癌驱动基因)、免疫组织化学(pERK、pVEGFR2、Ki67)、荧光原位杂交(VEGFA)和免疫组。
- 生成捕获索拉非尼治疗患者改善RFS的基因特征,使用Cox回归模型和交互作用检验评估预测和预后价值。
主要发现
- BIOSTORM重现了STORM的临床病理特征。
- 所检测的生物标志物(与血管生成和增殖相关)、既往提出的基因特征或突变均未预测索拉非尼获益或复发。
- 新生成的146基因特征识别30%的患者捕获索拉非尼在RFS方面的获益(交互作用p=0.04)。
- 这些索拉非尼RFS应答者显著富集CD4+ T细胞、B细胞和细胞溶解性自然杀伤细胞,且缺乏激活的适应性免疫成分。
- 肝细胞pERK(HR=2.41;p=0.012)和微血管侵犯(HR=2.09;p=0.017)为独立预后因素。
局限性
- 新生成的多基因特征与索拉非尼改善RFS相关,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic factors with B level of evidence. DESIGN: Tumour tissue from 188 patients randomised to receive sorafenib (83) or placebo (105) in the STORM trial was collected. Analyses included gene expression profiling, targeted exome sequencing (19 known oncodrivers), immunohistochemistry (pERK, pVEGFR2, Ki67), fluorescence in situ hybridisation (VEGFA) and immunome. A gene signature capturing improved RFS in sorafenib-treated patients was generated. All 70 RFS events were recurrences, thus time to recurrence equalled RFS. Predictive and prognostic value was assessed using Cox regression models and interaction test. RESULTS: BIOSTORM recapitulates clinicopathological characteristics of STORM. None of the biomarkers tested (related to angiogenesis and proliferation) or previously proposed gene signatures, or mutations predicted sorafenib benefit or recurrence. A newly generated 146-gene signature identifying 30% of patients captured benefit to sorafenib in terms of RFS (p of interaction=0.04). These sorafenib RFS responders were significantly enriched in CD4+ T, B and cytolytic natural killer cells, and lacked activated adaptive immune components. Hepatocytic pERK (HR=2.41; p=0.012) and microvascular invasion (HR=2.09; p=0.017) were independent prognostic factors. CONCLUSION: In BIOSTORM, only hepatocytic pERK and microvascular invasion predicted poor RFS. No mutation, gene amplification or previously proposed gene signatures predicted sorafenib benefit. A newly generated multigene signature associated with improved RFS on sorafenib warrants further validation. TRIAL REGISTRATION NUMBER: NCT00692770.
引用
- Pinyol R, Montal R, Bassaganyas L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2018. PMID: 30108162. doi:10.1136/gutjnl-2018-316408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。